STOCKS TELEGRAPH

Tag: NASDAQ:EWTX

  • Edgewise Therapeutics (EWTX) Stock Jumps After Positive Trial News

    Edgewise Therapeutics (EWTX) Stock Jumps After Positive Trial News

    As of the most recent check, shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) are up 10.72% in early session, trading at $30.58. Following the publication of positive results from the company’s clinical trial, EWTX shares increased.

    Landmark Results from Phase 2 CANYON Trial

    Edgewise Therapeutics (EWTX) unveiled positive topline results from its Phase 2 CANYON trial evaluating sevasemten in individuals with Becker muscular dystrophy (BMD). The goal of Sevasemten, a novel oral rapid skeletal myosin inhibitor, is to shield muscles from the harm that muscular dystrophies inflict due to contraction.

    Creatine kinase (CK) levels showed notable improvements from baseline, indicating that the experiment met its primary aim. The CANYON trial is noteworthy for being the first to effectively accomplish its primary aim and the biggest interventional study in BMD.

    Secondary endpoints also delivered promising insights. The North Star Ambulatory Assessment (NSAA) revealed a trend towards functional improvement in the sevasemten-treated group. Plasma fast skeletal muscle troponin I (TNNI2), a biomarker of acute skeletal muscle damage, showed significant reductions in comparison to the placebo group.

    Improvement was shown in functional assessments such the 10-meter walk/run, 4-stair climb, and 100-meter timed test. Crucially, compared to those in the placebo group, individuals undergoing therapy had more advanced illness.

    High Tolerance and Continued Engagement

    Sevasemten was well-tolerated across both adult and adolescent patient groups, with no new safety concerns reported. An impressive 99% of eligible participants from CANYON and other sevasemten trials have opted to enroll in MESA, an ongoing open-label extension study. This continued participation underscores confidence in the treatment’s safety and efficacy.

    Hope for a Transformative Therapy

    Becker muscular dystrophy remains an unmet medical need, with no approved therapies currently available. The groundbreaking results from the GRAND CANYON pivotal cohort signal the potential for sevasemten to stabilize functional decline in BMD patients.

    Edgewise Therapeutics plans to complete recruitment for the GRAND CANYON cohort by Q1 2025 and engage regulatory authorities for marketing authorization strategies in the U.S. and Europe. Additionally, EWTX intends to present the full CANYON study findings at an upcoming medical congress.

    Edgewise Therapeutics’ novel approach to treating muscular dystrophies highlights its potential to revolutionize care for Becker muscular dystrophy patients, offering hope for the first approved therapy in this challenging field.

  • Edgewise Therapeutics (EWTX) Experiences Stock Boost After Revealing Successful Trial Data

    Edgewise Therapeutics (EWTX) Experiences Stock Boost After Revealing Successful Trial Data

    The release of top-line data from clinical studies caused Edgewise Therapeutics, Inc. (NASDAQ: EWTX) shares to rise dramatically. During the Thursday session, EWTX stock price increased 54.69% to conclude at $29.50. The favorable results of a clinical study were the driving force behind that surge.

    What Edgewise Therapeutics has shared?

    Edgewise Therapeutics revealed key findings from the Phase 1 trial involving healthy subjects, as well as the single-dose component of the Phase 2 CIRRUS-HCM (obstructive hypertrophic cardiomyopathy) trial.

    EDG-7500 is designed as an oral, selective cardiac sarcomere modulator aimed at reducing early contraction velocity and improving impaired cardiac relaxation linked to HCM. The Phase 1 single ascending dose (SAD) trial had doses ranging from 5 to 300 mg for participants. The multiple ascending dosage (MAD) phase involved the administration of doses ranging from 25 to 100 mg once day for a total of 14 days.

    The absence of any alterations in clinical chemistry, electrocardiograms, or vital signs in either of the two trial segments demonstrated that EDG-7500 was well tolerated. Notably, the MAD portion demonstrated a half-life of approximately 30 hours, with steady-state concentrations achieved after about four days of dosing.

    Efficacy in Patients with Obstructive HCM

    Patients with obstructive HCM were given single doses of 50, 100, or 200 mg of EDG-7500 in the CIRRUS-HCM Part A experiment. There were notable decreases: for individuals taking the 100 and 200 mg dosages, there was a mean reduction in resting left ventricular outflow tract pressure gradient (LVOT-G) of 67% and a mean drop in provoked LVOT-G of 55%. Surprisingly, LVOT gradients below the 30 mmHg threshold were attained by 60% of patients receiving the larger dosages, and the medication had no negative effects on left ventricular ejection fraction (LVEF).

    Future Directions

    Edgewise Therapeutics is moving forward based on these promising results, initiating the 28-day segment of the CIRRUS-HCM trial in both obstructive and non-obstructive HCM patients. The company aims to further evaluate the tolerability, pharmacokinetics, and overall effects on cardiac metrics and biomarkers. Initial results from this segment are expected to be reported in the first quarter of 2025, with high hopes for EDG-7500 to advance the treatment landscape for HCM.